Stock Research for BLRX

BLRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BLRX Stock Chart & Research Data

The BLRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BLRX Due diligence Resources & Stock Charts

The BLRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BLRX Detailed Price Forecast - CNN Money CNN View BLRX Detailed Summary - Google Finance
Yahoo View BLRX Detailed Summary - Yahoo! Finance Zacks View BLRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BLRX Trends & Analysis - Trade-Ideas Barrons View BLRX Major Holders - Barrons
NASDAQ View BLRX Call Transcripts - NASDAQ Seeking View BLRX Breaking News & Analysis - Seeking Alpha
Spotlight View BLRX Annual Report - CompanySpotlight.com OTC Report View BLRX OTC Short Report - OTCShortReport.com
TradeKing View BLRX Fundamentals - TradeKing Charts View BLRX SEC Filings - Bar Chart
WSJ View Historical Prices for BLRX - The WSJ Morningstar View Performance/Total Return for BLRX - Morningstar
MarketWatch View the Analyst Estimates for BLRX - MarketWatch CNBC View the Earnings History for BLRX - CNBC
StockMarketWatch View the BLRX Earnings - StockMarketWatch MacroAxis View BLRX Buy or Sell Recommendations - MacroAxis
Bullish View the BLRX Bullish Patterns - American Bulls Short Pains View BLRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BLRX Stock Mentions - StockTwits PennyStocks View BLRX Stock Mentions - PennyStockTweets
Twitter View BLRX Stock Mentions - Twitter Invest Hub View BLRX Investment Forum News - Investor Hub
Yahoo View BLRX Stock Mentions - Yahoo! Message Board Seeking Alpha View BLRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BLRX - SECform4.com Insider Cow View Insider Transactions for BLRX - Insider Cow
CNBC View BLRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BLRX - OTC Markets
Yahoo View Insider Transactions for BLRX - Yahoo! Finance NASDAQ View Institutional Holdings for BLRX - NASDAQ


Stock Charts

FinViz View BLRX Stock Insight & Charts - FinViz.com StockCharts View BLRX Investment Charts - StockCharts.com
BarChart View BLRX Stock Overview & Charts - BarChart Trading View View BLRX User Generated Charts - Trading View




Latest Financial News for BLRX


BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
Posted on Wednesday March 27, 2024

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript March 26, 2024 BioLineRx Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2023 Financial […]


BLRX: First Aphexda Sales Recognized
Posted on Wednesday March 27, 2024

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Since the 3Q:23 report in November, BioLineRx Ltd. (NASDAQ:BLRX) has been focused on Aphexda commercialization following drug approval in September 2023. Since then, two other trials evaluating motixafortide have dosed first patients. One was the gene therapy trial in collaboration with the Washington University School of


BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
Posted on Tuesday March 26, 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates.


BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
Posted on Wednesday March 20, 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.